

# **Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/MF9FE9426ACEN.html>

Date: September 2018

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: MF9FE9426ACEN

## **Abstracts**

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2018

### **SUMMARY**

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Matrix metalloproteinase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization.

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Cardiovascular, Immunology, Infectious Disease, Ophthalmology, Respiratory and Undisclosed which include indications Neuropathic Pain (Neuralgia), Wounds, Adenocarcinoma Of The

Gastroesophageal Junction, Breast Cancer, Cancer Pain, Crohn's Disease (Regional Enteritis), Diabetic Neuropathic Pain, Dupuytren Contracture, Epilepsy, Fibrosis, Gastric Cancer, Herpes Labialis (Oral Herpes), Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Liver Fibrosis, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Myocardial Infarction, Opium (Opioid) Addiction, Osteoarthritis Pain, Pancreatic Islet Transplant Rejection, Peripheral Neuropathy (Sensory Neuropathy), Postherpetic Neuralgia, Pulmonary Fibrosis, Solid Tumor, Squamous Non-Small Cell Lung Carcinoma and Unspecified.

The latest report Matrix Metalloproteinase 9 - Pipeline Review, H2 2018, outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)

The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects

The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Overview

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics

Development

EA Pharma Co Ltd

Gilead Sciences Inc

Iproteos SL

NeuroMax Ltd

Shulov Innovative Science Ltd

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Drug Profiles

andecaliximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CALY-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPRO-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MMP9 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-336 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protearin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target MMP-9 for Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MMP2,9 and 13 for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Dormant Products

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Discontinued Products

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Product Development Milestones

Featured News & Press Releases

Nov 02, 2016: Abzena Provides Update on GS-5745

Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis

Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain

May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by EA Pharma Co Ltd, H2 2018  
Pipeline by Gilead Sciences Inc, H2 2018  
Pipeline by Iproteos SL, H2 2018  
Pipeline by NeuroMax Ltd, H2 2018  
Pipeline by Shulov Innovative Science Ltd, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Dormant Products, H2 2018 (Contd.2), H2 2018  
Discontinued Products, H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

EA Pharma Co Ltd

Gilead Sciences Inc

Iproteos SL

NeuroMax Ltd

Shulov Innovative Science Ltd

## I would like to order

Product name: Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/MF9FE9426ACEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF9FE9426ACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

